Episode
Episode 14: The Drug Discovery Problems AI Alone Can't Solve
- Podcast
- From Models to Medicine
- Published
- Jun 24, 2026
- Duration seconds
- 2747
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/from-models-to-medicine-7769799/episodes/episode-14-the-drug-discovery-problems-ai-alone-can-t-solve/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/from-models-to-medicine-7769799/episode-14-the-drug-discovery-problems-ai-alone-can-t-solve.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of From Models to Medicine, we speak with Vid Stojevic , the co-founder and CEO of Kuano, a Cambridge-based company using quantum algorithms and AI to tackle the drug discovery problems that traditional computational chemistry keeps failing. In this episode, he explains why he deliberately ignored the broad platform play and went narrow instead, targeting the specific early-stage problems where getting the physics right changes everything. We get into what a "quantum lens" actually means in practice, why transition states are a better design target than natural substrates, and how Kuano is succeeding on targets that pharma had written off as undruggable. Vid makes a sharp case for how generating synthetic quantum data turns a low-data drug discovery problem into something AI can actually work with. He closes with honest advice on when quantum simulation is the right tool and when it simply isn't.